Insider Selling: Ainos (NASDAQ:AIMD) Director Sells 109,988 Shares of Stock

Ainos, Inc. (NASDAQ:AIMD) Director Ting-Chuan Lee sold 109,988 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $1.90, for a total value of $208,977.20. Following the completion of the sale, the director owned 807,417 shares of the company’s stock, valued at $1,534,092.30. The trade was a 11.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Ainos Price Performance

Shares of NASDAQ AIMD traded down $0.60 during trading hours on Wednesday, reaching $2.56. The stock had a trading volume of 1,873,740 shares, compared to its average volume of 893,030. The business’s fifty day moving average price is $1.67 and its two-hundred day moving average price is $1.83. The company has a quick ratio of 0.50, a current ratio of 0.55 and a debt-to-equity ratio of 1.58. Ainos, Inc. has a 52-week low of $1.26 and a 52-week high of $4.50.

Ainos (NASDAQ:AIMD) last posted its earnings results on Wednesday, May 13th. The company reported ($0.41) earnings per share for the quarter. Ainos had a negative return on equity of 160.55% and a negative net margin of 11,912.10%.

Institutional Trading of Ainos

A number of hedge funds have recently bought and sold shares of AIMD. Mariner LLC purchased a new stake in Ainos during the fourth quarter worth $37,000. Two Sigma Investments LP purchased a new stake in shares of Ainos during the 3rd quarter valued at $80,000. DRW Securities LLC lifted its holdings in shares of Ainos by 272.6% during the 4th quarter. DRW Securities LLC now owns 66,211 shares of the company’s stock valued at $109,000 after purchasing an additional 48,439 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Ainos by 13.1% during the 4th quarter. Renaissance Technologies LLC now owns 66,300 shares of the company’s stock valued at $109,000 after purchasing an additional 7,700 shares during the last quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Ainos from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

About Ainos

Ainos, Inc (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format.